08 October 2024
08 October 2024
US hedge fund Starboard now holds 0.6% of Pfizer鈥檚 value as the drugmaker struggles with its post-pandemic financial performance.
The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.
The MHRA鈥檚 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies.
Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for survodutide as a treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis.
NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.
Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II breast cancer trial.
Apretude is indicated for preventing sexually transmitted HIV-1 infection in adults and adolescents.
ASK Pharm is entitled to receive upfront payments and milestone payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
